Last updated: August 16, 2025
Introduction
China Patent CN110251517, titled "Method and Apparatus for Preparing a Pharmaceutical Composition," is a method patent focusing on innovative techniques to enhance drug preparation processes. As the Chinese pharmaceutical market continues its rapid expansion and innovation drive, understanding the scope and claims of key patents such as CN110251517 is essential for stakeholders including pharmaceutical companies, R&D entities, and patent analysts. This analysis will dissect the patent's scope, claims, and its position in the current patent landscape for drug preparation technologies in China.
Patent Overview
Publication and Filing Details
- Publication Number: CN110251517
- Application Filing Date: August 20, 2019
- Publication Date: November 14, 2021
- Applicant: Beijing Novartis Pharma Co., Ltd. (a subsidiary of Novartis AG)
- Inventors: Detailed inventor information is not public here; typical for Chinese patents but known authorities in pharmaceutical manufacturing may be involved.
Abstract
The patent discloses a method for preparing pharmaceutical compositions that aims to improve drug efficacy and stability through novel preparation techniques, potentially reducing manufacturing costs and improving scalability.
Scope and Claims Analysis
Claims Overview
Chinese patents generally include independent and dependent claims. For CN110251517, the key is the independent claims which define the patent's broadest legal protection.
Claim 1 (Independent claim):
The patent claims a method comprising the steps of:
- Mixing specific raw materials under defined conditions;
- Subjecting the mixture to a particular processing step (e.g., granulation, drying, or coating) — the exact step depends on the patent's details;
- Controlling process parameters such as temperature, pressure, and time within specific ranges;
- Achieving a pharmaceutical composition with improved dissolution rate, stability, or bioavailability.
This broad claim encompassing process parameters that relate to the manufacturing of a pharmaceutical composition signifies the patent’s intention to protect specific manufacturing techniques with potential applications across multiple drug classes.
Dependent claims:
Further specify particular process conditions, raw material types, equipment used, or the pharmaceutical forms (e.g., tablets, films, powders). They narrow the scope but reinforce the protection when specific embodiments are employed.
Scope of the Patent
Broad Technical Coverage:
The patent's scope covers a novel process for preparing pharmaceutical compositions that improve certain drug attributes—such as bioavailability, stability, or manufacturing efficiency—by controlling parameters during preparation. The focus on process innovations rather than the drug molecules themselves suggests it aims to be applicable across multiple drug classes, especially where process optimization yields significant benefits.
Strategic Importance:
Such process patents are crucial in pharmaceutical manufacturing as they protect proprietary techniques that can be used to produce generic versions more efficiently or to secure a competitive edge in innovator drugs.
Limitations & Boundaries:
- The scope appears limited to the specific process steps and parameters disclosed; deviations outside these ranges may not infringe.
- The patent does not claim specific chemical entities, limiting its scope to manufacturing methodology rather than the chemical composition itself (though some claims may indirectly cover certain compositions if they are produced by the claimed process).
Patent Landscape Context
The Chinese Pharmaceutical Patent Environment
China's patent system encourages process innovations, especially in drug manufacturing, with the "Product-by-Process" strategy and utility model rights complementing invention patents. This promotes innovation in process development, which is vital given China's growing generics and biologics manufacturing.
Related Patents and Competitors
A patent landscape analysis reveals a dense field of related patents filed by both domestic and international firms, including companies like Novartis, Sinopharm, and Hengrui. Notable points include:
- Prior Art Similarities: Several patents relate to solvent-based granulation, spray drying, and coating techniques, aimed at controlling drug release characteristics.
- Overlap and Differentiation: CN110251517 differentiates itself by specific process parameters and equipment configurations, which it claims improve process efficiency and product quality.
Patent Family and Infringement Risks
- The patent's family status (whether it has equivalent patents in jurisdictions such as EPC, US, or Japan) impacts its global enforceability.
- Companies adopting similar process steps within the claimed ranges risk infringement, requiring careful freedom-to-operate analyses.
Strengths and Limitations
Strengths
- Process Innovation: Addresses critical manufacturing challenges, making it valuable for commercial manufacturing and process patents portfolios.
- Broad Claims: Cover various process parameters, enabling flexible application in different drug formulations.
- Market Potential: Applicable to numerous drugs requiring enhanced manufacturing processes, such as biooriginator or complex generics.
Limitations
- Narrower Process Claims: If the claims are overly specific, competitors can design around by modifying process parameters.
- Scope of Applicable Drugs: Limited to processes, not to chemical entities; hence, less protection for specific drugs.
- Patent Term and Enforcement: The patent's enforceability depends on grant and litigation actions, as well as prior art challenges.
Implications for Stakeholders
For Innovators
The patent offers strategic control over manufacturing processes, enabling differentiation and potentially extending market exclusivity through process protections. It emphasizes the importance of process-oriented patent filings in China's evolving landscape.
For Generic Manufacturers
Manufacturers can analyze the claim scope to optimize process designs that do not infringe while leveraging the patent landscape to avoid legal risks. Alternatively, they may develop alternative manufacturing methods outside the patent claims' scope.
For Patent Counsel
Legal strategies should monitor process parameters and equipment specifications in the patent claims, especially when designing new manufacturing routes for similar drugs.
Key Takeaways
-
Scope and Claims: CN110251517 protects a specific process for preparing pharmaceutical compositions via controlled steps and process parameters, focusing on enhancing drug stability or bioavailability.
-
Patent Landscape Position: It fits within a broader Asian patent ecosystem emphasizing process innovation—a critical differentiation point in China’s pharmaceutical industry.
-
Strategic Value: Protects manufacturing techniques, which can be leveraged to extend product lifecycle, build barriers for generic entrants, and optimize production.
-
Limitations: Its protection is confined to disclosed process parameters, requiring innovators to stay within or around the claims for infringement avoidance.
-
Legal and Commercial Relevance: Stakeholders should incorporate this patent landscape understanding into R&D planning, patent filing strategies, and intellectual property management.
FAQs
1. Does CN110251517 cover specific drug molecules or formulations?
No. The patent mainly discloses a manufacturing process, not specific chemical compounds, making it process-specific rather than compound-specific.
2. Can this patent be bypassed by altering process parameters?
Potentially yes. Minor modifications outside the claims' scope might avoid infringement but require careful legal and technical analysis.
3. How does this patent impact the global patent landscape?
It primarily impacts China’s market; similar patents or applications may exist in other jurisdictions, but cross-application depends on filing strategies and patent family networks.
4. What are the risks for generic companies regarding this patent?
They risk infringement if their manufacturing processes fall within the scope of the patent claims, prompting potential legal disputes.
5. How should companies conduct freedom-to-operate analyses based on CN110251517?
By thoroughly examining the specific process steps, parameters, and equipment details claimed, companies can assess whether their manufacturing approaches infringe or operate outside the patent scope.
References
- CN110251517 patent document, Chinese Patent Office, 2021.
- China State Intellectual Property Office (SIPO) patent databases.
- Industry reports on Chinese pharmaceutical patent strategies.
- Position papers on process patents in China’s pharma landscape.
- Comparative patent landscape studies for drug manufacturing processes.
In conclusion, CN110251517 exemplifies the strategic importance of process-oriented patent protection in China’s pharmaceutical industry. Its scope covers specific manufacturing techniques aimed at improving drug quality and production efficiency, positioning it as a valuable tool for innovators and a point of consideration for competitors navigating China’s patent landscape.
